Human epidermal growth factor receptor 2 (HER 2) is an important immunohistochemical (IHC) biomarker for breast cancer (BC) to determine the eligibility of HER 2 targeted therapies both for classical HER 2 overexpression and HER 2 low status For correct treatment decision, accurate and precise HER 2 IHC testing is fundamental. In this study, we evaluated if cell lines with relevant and critical expression levels of HER 2 in combination with artificial intelligence (AI) could be used to identify inaccurate HER 2 IHC assays.

Birgit Truumees¹, Jeppe Thagaard², Stine Amtoft Nielsen², Mateusz Tylicki², Lise Emanuelsen¹, Søren Nielsen¹

1. NordiQC, Department of Pathology, Aalborg University Hospital, Denmark
2. Visiopharm A/S, Denmark

Disclosures:
Birgit Truumees: None; Jeppe Thagaard: Employee, Visiopharm A/S; Stine Amtoft Nielsen: Employee, Visiopharm A/S; Mateusz Tyli ck i: Employee, Visiopharm A/S; Lise Emanuelsen: None; Søren Nielsen: None.